121 related articles for article (PubMed ID: 22922775)
1. Evaluation of adrenal reserve in children with acute lymphocytic leukemia treated with prednisone or dexamethasone.
Kuperman H; Odone Filho V; Cristofani LM; Assis de Almeida MT; Setian N; Damiani D
Horm Res Paediatr; 2012; 78(2):73-80. PubMed ID: 22922775
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of corticosteroid-induced adrenal suppression during treatment for acute lymphoblastic leukemia in children: a prospective observational study using the low-dose adrenocorticotropin test.
Rix M; Birkebaek NH; Rosthøj S; Clausen N
J Pediatr; 2005 Nov; 147(5):645-50. PubMed ID: 16291357
[TBL] [Abstract][Full Text] [Related]
3. Impaired adrenal function after glucocorticoid therapy in children with acute lymphoblastic leukemia.
Petersen KB; Müller J; Rasmussen M; Schmiegelow K
Med Pediatr Oncol; 2003 Aug; 41(2):110-4. PubMed ID: 12825213
[TBL] [Abstract][Full Text] [Related]
4. Suppression of adrenal function in children with acute lymphoblastic leukemia following induction therapy with corticosteroid and other cytotoxic agents.
Mahachoklertwattana P; Vilaiyuk S; Hongeng S; Okascharoen C
J Pediatr; 2004 Jun; 144(6):736-40. PubMed ID: 15192618
[TBL] [Abstract][Full Text] [Related]
5. Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia.
Einaudi S; Bertorello N; Masera N; Farinasso L; Barisone E; Rizzari C; Corrias A; Villa A; Riva F; Saracco P; Pastore G
Pediatr Blood Cancer; 2008 Mar; 50(3):537-41. PubMed ID: 17828747
[TBL] [Abstract][Full Text] [Related]
6. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.
Rensen N; Gemke RJ; van Dalen EC; Rotteveel J; Kaspers GJ
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD008727. PubMed ID: 29106702
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the hypothalamic-pituitary-adrenal axis in children with leukemia before and after 6 weeks of high-dose glucocorticoid therapy.
Kuperman H; Damiani D; Chrousos GP; Dichtchekenian V; Manna TD; Filho VO; Setian N
J Clin Endocrinol Metab; 2001 Jul; 86(7):2993-6. PubMed ID: 11443157
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of hypothalamic-pituitary-adrenal axis recovery after corticotherapy by using basal cortisol secretion].
Silva IN; Cunha CF; Finch FL; Colosimo EA
Arq Bras Endocrinol Metabol; 2006 Feb; 50(1):118-24. PubMed ID: 16628284
[TBL] [Abstract][Full Text] [Related]
9. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.
Gordijn MS; Rensen N; Gemke RJ; van Dalen EC; Rotteveel J; Kaspers GJ
Cochrane Database Syst Rev; 2015 Aug; (8):CD008727. PubMed ID: 26282194
[TBL] [Abstract][Full Text] [Related]
10. Time course of recovery of adrenal function in children treated for leukemia.
Felner EI; Thompson MT; Ratliff AF; White PC; Dickson BA
J Pediatr; 2000 Jul; 137(1):21-4. PubMed ID: 10891816
[TBL] [Abstract][Full Text] [Related]
11. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.
Gordijn MS; Gemke RJ; van Dalen EC; Rotteveel J; Kaspers GJ
Cochrane Database Syst Rev; 2012 May; (5):CD008727. PubMed ID: 22592733
[TBL] [Abstract][Full Text] [Related]
12. Duration of adrenal insufficiency during treatment for childhood acute lymphoblastic leukemia.
Vestergaard TR; Juul A; Lausten-Thomsen U; Lausen B; Hjalgrim H; Kvist TK; Andersen EW; Schmiegelow K
J Pediatr Hematol Oncol; 2011 Aug; 33(6):442-9. PubMed ID: 21792040
[TBL] [Abstract][Full Text] [Related]
13. [Is there a risk of steroid-induced adrenal deficit after induction treatment of acute lymphoblastic leukemia?].
Bélien-Pallet V; Cabrol S; Fasola S; Petit A; Landman-Parker J; Auvrignon A; Leverger G
Arch Pediatr; 2010 Dec; 17(12):1637-44. PubMed ID: 20943354
[TBL] [Abstract][Full Text] [Related]
14. Single-dose oral dexamethasone in the emergency management of children with exacerbations of mild to moderate asthma.
Altamimi S; Robertson G; Jastaniah W; Davey A; Dehghani N; Chen R; Leung K; Colbourne M
Pediatr Emerg Care; 2006 Dec; 22(12):786-93. PubMed ID: 17198210
[TBL] [Abstract][Full Text] [Related]
15. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia.
Hurwitz CA; Silverman LB; Schorin MA; Clavell LA; Dalton VK; Glick KM; Gelber RD; Sallan SE
Cancer; 2000 Apr; 88(8):1964-9. PubMed ID: 10760775
[TBL] [Abstract][Full Text] [Related]
16. Short-term effects on linear growth and bone turnover in children randomized to receive prednisolone or dexamethasone.
Ahmed SF; Tucker P; Mushtaq T; Wallace AM; Williams DM; Hughes IA
Clin Endocrinol (Oxf); 2002 Aug; 57(2):185-91. PubMed ID: 12153596
[TBL] [Abstract][Full Text] [Related]
17. Early adrenocortical recovery after glucocorticoid therapy in children with leukemia.
Cunha Cde F; Silva IN; Finch FL
J Clin Endocrinol Metab; 2004 Jun; 89(6):2797-802. PubMed ID: 15181060
[TBL] [Abstract][Full Text] [Related]
18. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol.
Igarashi S; Manabe A; Ohara A; Kumagai M; Saito T; Okimoto Y; Kamijo T; Isoyama K; Kajiwara M; Sotomatsu M; Sugita K; Sugita K; Maeda M; Yabe H; Kinoshita A; Kaneko T; Hayashi Y; Ikuta K; Hanada R; Tsuchida M
J Clin Oncol; 2005 Sep; 23(27):6489-98. PubMed ID: 16170158
[TBL] [Abstract][Full Text] [Related]
19. Differential antileukemic activity of prednisolone and dexamethasone in freshly isolated leukemic cells.
Mihál V; Hajdúch M; Nosková V; Feketová G; Jess K; Gojová L; Kaspárek I; Starý J; Blazek B; Pospísilová D; Novák Z
Adv Exp Med Biol; 1999; 457():461-71. PubMed ID: 10500823
[TBL] [Abstract][Full Text] [Related]
20. High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone.
Goto M; Miyagawa N; Kikunaga K; Miura M; Hasegawa Y
Endocr J; 2015; 62(2):145-51. PubMed ID: 25342092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
